Drug Trial Radar · NCT06270225
A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
Last checked: Nov 19, 2026Latest source record: Aug 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
157
Actual
Start
Mar 30, 2024
Primary completion
Oct 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.
Conditions
- Gout Arthritis
Interventions
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mgDrug
Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mgDrug
Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
Colchicine 0.5 mgDrug
Subjects will receive 0.5mg/d Colchicine for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of acute gout flaresTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Huashan Hospital Fudan University-Rheumatology
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.